comparemela.com
Home
Live Updates
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors : comparemela.com
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
/PRNewswire/ -- KAHR, a clinical-stage biotech company developing DSP107, a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and...
Related Keywords
Chicago
,
Illinois
,
United States
,
Modiin
,
Israel General
,
Israel
,
American
,
Tsipi Haitovsky
,
Yaron Pereg
,
American Society Of Clinical Oncology
,
American Society
,
Clinical Oncology
,
Chief Executive Officer
,
Developmental Therapeutics
,
Kahr Medical
,
comparemela.com © 2020. All Rights Reserved.